Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Q2/2023 earnings reporting date announcements

July 31, 2023 7:19am

Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings or LPS (loss-per-share) meet or fall short of consensus and expectation

MiMedx (MDXG) 8/1 Tuesday

Editas Medicine (EDIT), Blueprint Medicine (BPMC), Regenxbio (RGNX) and Vericel (VCEL) 8/2 Wednesday

Alnylam Pharmaceuticals (ALNY), Voyager Therapeutics (VYGR), Ultragenyx (RARE), Intellia Therapeutics (NTLA), Cellectis SA (CLLS) 8/3 Thursday

Axogen (AXGN), 8/7 Monday

Agenus (AGEN), Beam Therapeutics (BEAM), BioLife Solutions (BLFS), Fate Therapeutics (FATE), Verve Therapeutics (VERV) and bluebird bio (BLUE) 8/8 Tuesday

Ionis Pharmaceuticals (IONS) 8/9 Wednesday

Prime Medicine (PRME) 8/10 Thursday

CRISPR Therapeutics (CRSP) 8/14 Monday

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.